Sirion launches trial

Article

Sirion Therapeutics has begun enrolment for a Phase II trial of the compound fenretinide, as a treatment for geographic atrophy in patients with age-related macular degeneration.

Related Videos
Josefina Botta, MD, MSc, at ASCRS 2024
Related Content
A cell in amniotic fluid. Image credit: ©Icruci – stock.adobe.com

Amniotic membrane could move the needle outside of the operating room

April 19th 2024
Article

The tissue serves as a testing ground for outpatient ocular therapies

Site Logo

Novel Therapies in Neovascular AMD and DME: Achieving Superior Anatomic Outcomes with Fewer Injections

June 29th 2023
Podcast
Lohith Shetty. Image courtesy of SCHWIND

SCHWIND appoints new head of global marketing solutions

April 17th 2024
Article

Lohith Shetty will lead marketing for the company, based in Kleinostheim, Germany

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

December 19th 2022
Podcast
A patient with a mask has closed eyes. Image credit: ©Ayman Alakhras – stock.adobe.com

Cataract surgery pre-treatment with miLoop: Shorter lensectomy time, less irrigation needed

April 6th 2024
Article

Investigators presented research on the pre-treatment outcomes during the 2024 ASCRS meeting

To Infinity and (PRES)BYOND - The game changer for my practice

To Infinity and (PRES)BYOND - The game changer for my practice

April 4th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.